New asthma drug aims to slash severe attacks in Hard-to-Treat patients
NCT ID NCT06488755
First seen Apr 12, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests an experimental drug called SIM0718 for adults and teens (ages 12–75) with severe eosinophilic asthma that is not well controlled by current inhalers. Participants will receive either SIM0718 or a placebo alongside their usual medications. The main goal is to see if SIM0718 reduces the number of severe asthma attacks over one year and improves breathing. About 418 people will take part in this Phase 3 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA; EOSINOPHILIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
China Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact
Conditions
Explore the condition pages connected to this study.